CSIMarket Company Name, Ticker, Industry, else..
 
Zura Bio Limited  (NASDAQ: ZURA)
 
Price: $5.2600 $0.05 0.960%
Day's High: $5.349999904632568 Week Perf: -14.19 %
Day's Low: $ 5.15 30 Day Perf: -6.57 %
Volume (M): 469,374 52 Wk High: $ 7.44
Volume (M$): $ 0 52 Wk Avg: $4.92
Open: $5.21 52 Wk Low: $1.88



 Market Capitalization (Millions $) 667
 Shares Outstanding (Millions) 127
 Employees 40
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -112
 Cash Flow (TTM) (Millions $) 71
 Capital Exp. (TTM) (Millions $) 0

Business Description


Zura Bio Limited is a biotechnology company that specializes in the discovery and development of novel therapeutics. They focus on developing innovative treatments for diseases with unmet medical needs, particularly in the areas of oncology and autoimmune disorders. The company utilizes advanced technologies and cutting-edge research methodologies to identify and optimize potential drug candidates. Zura Bio Limited aims to improve patient outcomes and quality of life through its commitment to scientific excellence and the development of safe and effective therapies.


   Company Address: 1489 W. Warm Springs Rd. #110 Henderson 89014 NV
   Company Phone Number: 825-9872   Stock Exchange / Ticker: NASDAQ ZURA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -13.21%    
EXEL   -4.59%    
GILD   -3.88%    
HALO   -1.78%    
IOVA        5.52% 
RXRX   -6.34%    
• View Complete Report
   



Business Update

“Zura Bio Limited Navigating Financial Waters with Resilience in Q3 2025”

Published Thu, Nov 13 2025 1:40 PM UTC

Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates In a recent announcement, Zura Bio Limited (NASDAQ: ZURA) reported its financial results for the third quarter of 2025, revealing critical insights into the company’s performance and strategic direction. With 94.29 million shares outstanding, Zura Bio has established its current stock price ...
Business Update

Zura Bio Limited Strategic Inducement Grants Amidst Steady Revenue in Competitive Landscape

Published Fri, Jul 18 2025 8:27 AM UTC

In the fast-paced world of biotech, Zura Bio Limited (Nasdaq: ZURA), a clinical-stage company specializing in multi-asset immunology and the development of novel dual-pathway antibodies, has made noteworthy strides in its recent corporate developments. As the company continues its pursuit of innovative solutions for autoimmune and inflammatory diseases, it concurrently addre...
Business Update

Zura Bio Advances Immunology Efforts with FDA Submission and Strategic Warrants Exchange,

Published Thu, Nov 14 2024 11:40 PM UTC

In a pivotal move for the clinical-stage immunology field, Zura Bio Limited (Nasdaq: ZURA) has announced the submission of a protocol for a Phase 2 study of tibulizumab to the U.S. Food and Drug Administration (FDA). Tibulizumab is a cutting-edge humanized tetravalent bispecific dual antagonist antibody, which uniquely neutralizes both IL-17A and another yet-to-be-disclosed ...
Business Update

Zura Bio Reports Promising Q2 2024 Developments Amid Promising Clinical Progress for Autoimmune Therapies

Published Tue, Aug 13 2024 3:47 PM UTC

Zura Bio s Strategic Advancements in Immunology: A Comprehensive Overview of Q2 2024 Financial Results and Key Clinical Progressions HENDERSON, Nev. Zura Bio Limited (Nasdaq: ZURA), a pioneering clinical-stage immunology company, has revealed its second quarter 2024 financial results, accompanied by significant business highlights that showcase the company s commitment to ...
Business Update

Zura Bio Updates Stakeholders on Successful Warrant Exchange Offer and Consent Solicitation, Strengthening Ca...

Published Sun, Aug 11 2024 5:32 PM UTC

HENDERSON, Nev. Zura Bio Limited (Nasdaq: ZURA), a leading clinical-stage immunology company specializing in the development of innovative dual-pathway antibodies for the treatment of autoimmune and inflammatory diseases, has announced the expiration and results of its previously proposed exchange offer (the Exchange Offer) and consent solicitation (the Consent Solicitatio...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 3.38
PEG (TTM) -

Financial Strength Current
Quick Ratio 9.46
Working Capital Ratio 9.7
Leverage Ratio (MRQ) 0.11
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.13 $
Revenues (TTM) -
Cash Flow (TTM) 0.56 $
Cash 1.62 $
Book Value 1.55 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -2,789,425
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.